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This systematic review synthesizes the diverse body of epidemiologic research accrued on inorganic
arsenic exposure and respiratory health effects. Twenty-nine articles were identiﬁed that examined the
relationship between inorganic arsenic exposure and respiratory outcomes (i.e. lung function, symptoms,
acute respiratory infections, chronic non-malignant lung diseases, and non-malignant lung disease
mortality). There was strong evidence of a general association between arsenic and non-malignant re-
spiratory illness, including consistent evidence on lung function impairment, acute respiratory tract
infections, respiratory symptoms, and non-malignant lung disease mortality. Overall, early life exposure
(i.e. in utero and/or early-childhood) had a marked effect throughout the lifespan. This review also
identiﬁed some research gaps, including limited evidence at lower levels of exposure (water arsenic
< μ100 g/L), mixed evidence of sex differences, and some uncertainty on arsenic and any single non-
malignant respiratory disease or pathological process. Common limitations, including potential pub-
lication bias; non-comparability of outcome measures across included articles; incomplete exposure
histories; and limited confounder control attenuated the cumulative strength of the evidence as it relates
to US populations. This systematic review provides a comprehensive assessment of the epidemiologic
evidence and should be used to guide future research on arsenic's detrimental effects on respiratory
health.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The World Health Organization (WHO) lists inorganic arsenic
(InAs) as one of 10 chemicals of major public health concern
(World Health Organization, 2010b). Arsenic is a naturally occur-
ring yet life-threatening toxicant to which millions are inad-
vertently exposed annually (World Health Organization, 2010a).
Arsenic contaminates the groundwater (wAs) of many countries,
including Bangladesh, Chile, China, India, Mexico, Central Europe,
and the United States, at levels which exceed the WHO standard of
μ10 g/L (World Health Organization, 2010a).
The International Agency for Research on Cancer classiﬁes InAs
and arsenic compounds as group 1 lung carcinogens, meaning
there is sufﬁcient evidence to conclude that InAs exposure from
inhalation and ingestion causes lung cancer in humans (Interna-
tional Agency for Research on Cancer, 2009). Presently, InAs is the
only group 1 lung carcinogen known to be active by both inhala-
tion and ingestion (Smith et al., 2009). Compared to the body ofr Inc. This is an open access article
. Sanchez),research on InAs and lung cancer, however, the body of research
on InAs and non-malignant lung disease is less cohesive and more
difﬁcult to characterize.
One of the ﬁrst studies on InAs exposure and respiratory health
dates back to the 1970s in Chile. In 1958 the city of Antofagasta
started supplementing its main water supply (wAs levels around
μ90 g/L) with river water (wAs levels near μ1000 g/L) to accom-
modate the city's growing population (Smith et al., 2006; Borgoño
et al., 1977; Zaldivar, 1980). By 1971 a water treatment plant had
been installed and wAs levels were gradually returned to pre-1958
levels. However, during the intervening period before the water
was treated, lasting from 1958 to 1970, all residents of Antofagasta,
Chile consumed very high levels of InAs ( > μ )wAs 800 g/L in their
drinking water (Borgoño et al., 1977). In Borgoño et al. (1977),
which occurred several years after peak exposure, children with
arsenical skin lesions had a greater prevalence of broncho-
pulmonary disease history and chronic cough compared to chil-
dren who did not have arsenical lesions. Although symptoms and
functional disabilities associated with non-malignant lung disease
generally appear in late adulthood, the Antofagasta study began
shedding light on an important result – that developing lungs are
particularly vulnerable early in life and that InAs exposure in utero
and during childhood can have life-long consequences.under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Eligibility criteria and objectives created a priori using adapted PICOS format.
Topic Question Exclude if…
Participants Are the study participants human? Not human
Exposure Does the article have a relevant exposure measurement? No measure of exposure (or occupationally/ ATO
chemotherapy exposed)
Comparisons Does the article have a control or referent group? No reference group (i.e. case study or case report)
Outcome Does the article have a relevant outcome (i.e. lung function, respiratory symptoms, acute respiratory
infections, chronic non-malignant lung disease, and non-malignant respiratory mortality)?
Not relevant
Study design Does the article report primary data? No primary data
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lung disease, published almost a decade ago (Guha Mazumder,
2007), but no systematic reviews or meta-analyses have sum-
marized the evidence on this body of research. Instead of focusing
on a singular aspect of non-malignant lung disease, this systematic
review holistically describes the relationship between InAs and
non-malignant lung disease, and also groups respiratory health
diseases into easily interpretable categories, including lung func-
tion, respiratory symptoms, acute respiratory tract infections,
chronic non-malignant lung diseases and non-malignant lung
disease mortality. We deﬁne respiratory health quite broadly but
because this outcome is inherently heterogeneous, encompassing
numerous phenotypes among people of different ages and various
disease trajectories, there may be additional non-malignant lung
disease outcomes which we have unintentionally neglected in this
review.
Responding to a U.S. congressional mandate, the U.S. National
Research Council convened a group of experts in 2012 to evaluate
and guide the Environmental Protection Agency's (EPA) Integrated
Risk Information System's (IRIS) toxicological assessment of InAs
(National Research Council, 2014). The National Research Council
recommended the EPA conduct systematic reviews on 18 health
endpoints of concern, including non-malignant respiratory effects,
to support the agency's assessment. Several published systematic
reviews and meta-analyses have already synthesized the epide-
miological evidence on the relation between InAs and other health
consequences, including lung cancer (Celik et al., 2008), skin le-
sions and skin cancers (Karagas et al., March 2015), cardiovascular
disease (Navas-Acien et al., 2005; Moon et al., 2012), hypertension
(Abhyankar et al., 2012), adverse pregnancy outcomes (Quansah
et al., 2015), chronic kidney disease (Zheng et al., 2014), urinary
tract cancers (Saint-Jacques et al., 2014), and type-2 diabetes
(Navas-Acien et al., 2006). A systematic review on InAs and re-
spiratory health is greatly needed.
We implemented a systematic approach to identify, evaluate,
and synthesize the epidemiologic evidence on this body of re-
search to better understand the effects of InAs exposure on dif-
ferent parameters of non-malignant lung disease in InAs-affected
populations. We also examined whether there are timing-, dose-
and sex-speciﬁc effects.2. Methods
2.1. Search selection
We implemented an extensive search strategy with guidance
from a Reference Librarian at Columbia University Medical Center
and in accordance with PRISMA guidelines (Moher et al., 2009):
 Systematic searches in two bibliographic databases:
MEDLINE/PUBMED (http://www.ncbi.nlm.nih.gov/pubmed).
EMBASE (http://www.elsevier.com/solutions/embase).
 Gray literature searches using Google Scholar and Web ofKnowledge's Citation Network.
 Handsearches of the references of included publications.
For bibliographic databases, our search combined comprehen-
sive English terms representing non-malignant respiratory health
effects with terms for InAs exposure with the Boolean operator
AND (see supplementary material for complete list of search
terms). Before conducting a full search, we piloted our search and
made slight modiﬁcations to meet the speciﬁc needs of each da-
tabase search whenever necessary. We conducted two searches on
each bibliographic database. We used both keywords and MeSH
terms for PubMed, and similarly for EMBASE, we used keyword
and EMTREE/exp terms. Searches were limited to English-lan-
guage articles published before January 2016. Articles had to meet
the following a priori criteria to be eligible for inclusion: (1) con-
tained original human-based research published in a peer-re-
viewed journal; (2) had a control or referent group; and (3) in-
cluded an indicator of InAs exposure studied in relation to any one
or more of the following outcome categories listed in Table 1.
We downloaded our search results using Endnote and subse-
quently transferred the references to DistillerSR for title and ab-
stract screening (http://distillercer.com/products/distillersr-sys
tematic-review-software/). After removing exact article duplicates,
TS screened all titles and abstracts (if available). JG and MP con-
ducted a blinded independent random check on 20% of the initial
search results, with 100% concordance between authors for in-
cluded and excluded articles. Articles which met the initial
screening stages underwent full-text review by all authors.
During the full-text review, we assessed whether multiple
publications from the same study population contained duplicate
data. We identiﬁed multiple publications of the same study
(“study” meaning effort to collect primary data and “publication”
meaning effort at analyzing the data) by examining author af-
ﬁliation, study design, cohort name, enrollment criteria, and en-
rollment dates. When there were multiple publications reporting
on the same study we described the relevant publications and
noted potential overlap in the results section.
2.2. Data extraction
We created and piloted a data extraction form using DistillerSR.
The piloted form was then modiﬁed to ﬁt our needs. TS extracted
information from each article and co-authors spot-checked data
extraction.
For publications that examined either exposure or outcome
categorically, we presented evidence from the highest category vs.
the lowest category. We performed additional subgroup analyses
on (1) critical periods of exposure (i.e. in utero and early life ex-
posure); (2) sex differences; and (3) low level InAs exposure
( < μ )wAs 100 g/L . We speciﬁed all subgroup analyses a priori. We
deemed a meta-analysis inappropriate due to the heterogeneous
nature of the available publications.
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Although no consensus exists on the ideal checklist and scale
for assessing methodological quality (Moja et al., 2005), we de-
veloped our quality appraisal criteria from existing systematic
reviews on InAs exposure (Navas-Acien et al., 2005; Zheng et al.,
2014). Quality assessment questions were divided into ﬁve cate-
gories: exposure assessment, outcome assessment, statistical
analysis, data collection, and speciﬁc questions for longitudinal
studies. Exposure assessment for each study is also described in
greater detail in results subsections. All authors independently
assessed both the quality and risk of bias for each publication.
Together authors resolved any disagreements and discussed any
potential risk of bias that may have been overlooked.Fig. 1. Publication selection process used in the systematic review on the association be
total 29 because an article may have included multiple outcomes.3. Results
3.1. Overview
The results from our systematic search are diagrammed in
Fig. 1. Our full search retrieved a total of 3787 titles and abstracts
fromwhich 50 publications met preliminary screening criteria and
received full-text review. Our ﬁnal review included 29 publications
from eight countries. Eight publications were from India, nine
were from Bangladesh, four were from Chile, three were from the
USA, two were from China, and one from Taiwan, Pakistan and
Mexico. Articles were published in 21 different journals between
1998 and 2015. Sixteen publications were cross-sectional, eight
were longitudinal, four were ecological, and one was case-control.
Exposure also varied widely by timing, duration and level of
exposure. Several publications reported more than one relevant
endpoint category: nine publications examined lung function,tween InAs and respiratory health. Categories under the “included” heading do not
T.R. Sanchez et al. / Environmental Research 147 (2016) 537–555540eighteen examined respiratory symptoms, seven examined acute
respiratory tract infections, six examined chronic non-malignant
lung disease, and ﬁve examined non-malignant lung disease
mortality.
3.1.1. Sub-analyses of interest
Nine articles examined the implications from in utero/early life
InAs exposure at different lifestages, including endpoints during
infancy (Farzan et al., 2013, 2015; Rahman et al., 2011; Raqib et al.,
2009), childhood (Recio-Vega et al., 2014; Smith et al., 2013), and
adulthood (Dauphine et al., 2011; Smith et al., 2006, 2011). Thir-
teen publications stratiﬁed their results by sex (Parvez et al., 2013;
Pesola et al., 2012; Dauphine et al., 2011; Smith et al., 1998, 2006,
2011; Raqib et al., 2009; Mazumder et al., 2000, 2005; von Eh-
renstein et al., 2005; Milton et al., 2001; Tsai et al., 1999). One
publication examined the relationship between arsenic metabo-
lism and lung function (Recio-Vega et al., 2014). Four articles ex-
amined the effects of < μInAs 100 g/L (Farzan et al., 2013, 2015;
Feng et al., 2015; Das et al., 2014).
3.1.2. Quality assessment
Fig. 2 shows the quality assessment overview for each pub-
lication. Each results subsection applied a more rigorous quality
assessment for select publications.
Seventeen publications assessed InAs exposure at the in-
dividual level. The remaining twelve assessed InAs exposure eco-
logically or by arsenical skin lesion status. Most publications had
either an incomplete exposure history or did not include exposure
from all major sources (water and diet). In general, publications
with incomplete exposure histories either had a measure of cur-
rent urinary arsenic (uAs) or wAs measurements (and/or recent
exposure history) but had no record or early life exposure. Alter-
natively, publications had a measure of pre-natal/early life InAs
exposure, but did not have a measurement of later life exposure/
exposure contemporaneous with the outcome. Therefore pub-
lications using a marker of early-life exposure did not necessarilyFig. 2. Quality assessment ainclude all major exposure sources throughout the life course.
Additionally, dietary InAs exposure is a growing concern as a
signiﬁcant contributor to exposure, especially when InAs levels in
drinking water are low. Thus publications which incorporated a
biomarker of exposure and reported on prior InAs exposure levels,
including exposure throughout the life course, had higher quality
exposure assessment than publications which only classiﬁed InAs
exposure according to wAs levels or which used an isolated
measurement of uAs.
Respiratory symptom questionnaires and lung function mea-
surements were generally standardized; however, most outcomes
on chronic lung disease were self-reported or gleaned through
death records and verbal autopsies. Diagnostic criteria for several
outcomes, including chronic bronchitis and pneumonia were in-
consistent across publications, thus increasing uncertainty in our
classiﬁcation by outcome (respiratory symptom vs. acute re-
spiratory infection vs. chronic respiratory disease) and making
comparisons between publications challenging.
All but two publications presented internal comparisons be-
tween study groups. Most publications adequately controlled for
important potential confounders, including age, sex, and smoking.
Participant selection criteria and participation rates were variably
reported across publications. Among the eight cohort publications
all but three reported follow-up rates and described how those
lost to follow-up compared to those remaining in the study. It was
often unclear whether the person in charge of collecting in-
formation on disease status was blinded to exposure status. Sev-
eral articles failed to report both adjusted and unadjusted results.
These methodological limitations attenuated the cumulative
strength of the evidence on InAs and non-malignant lung disease.
Overall, this systematic review includes articles of both high
quality (robust exposure assessment, adjustment for potential
confounders and standardized outcome measures) and low quality
(incomplete exposure assessment/history, no adjustment for po-
tential confounders, and non-standardized outcome metrics).t the publication-level.
Table 2
Evidence table on InAs and lung function.
Reference Location Age (yrs) Exposure level Outcome Effect estimate 95%CI/ Comments
Study design Size Male (%) p-Value
−Ecological level water arsenic publications
Das et al. (2014) India Exp: Adults wAs:11–50 FEV1 (L) Mean Diff 16 <p 0.0001 Unadjusted. Also %pred, obstructive, restrictive, FEF25–75 and PEFR.
Cross-sectional n¼834 Out: Adults vs. FVC (L) Mean Diff 18 <p 0.0001
Male:100 <wAs 10
Dauphine et al. (2011) Chile Exp:in utero >wAs 800 FEV1 (%pred) Mean Diff 8.0 p¼0.05 Adj: smoking, air pollution, education. Also reports stratiﬁed by sex and smoking.
Cross-sectional n¼97 Out:32–65 vs. FVC (%pred) Mean Diff 7.9 p¼0.05
Male:38 ≤wAs 250
−Individual level water arsenic publications
Smith et al. (2013) Bangladesh Exp:in utero ≥wAs 500 FEV1 (mL) Mean Diff 22.6 72.7, 27.6 Adj: age, gender, height, weight, parents' education, father's smoking, rooms in house.
Longitudinal n¼650 Out:7–17 vs. FVC (mL) Mean Diff 17.2 71.6, 37.3
Male:52 <wAs 10
Nafees et al. (2011) Pakistan ≥Exp: 15 ≥wAs 250 FEV1(mL) Risk ratio 226.4 430.4, 22.4 Adj: age, sex, height, smoking. Also reports R2 values.
Cross-sectional n¼200 ≥Out: 15 vs. FVC (mL) Risk ratio 354.8 583.6,
126.0
Male:46 <wAs 10 FEV1/FVC Risk ratio 9.9 21.8, 41.6
von Ehrenstein et al.
(2005)
India ≥Exp: 20 ≥wAs 400 FEV1 (mL) Mean Diff 194.7 353.9, 35.5 Showing males only. Adj: age, height, and smoking. Also reports results by skin lesions and sex
stratiﬁed.
Cross-sectional n¼178 ≥Out: 20 vs. FVC (mL) Mean Diff 83.8 261.5, 93.8
Male:62 <wAs 100
Urinary arsenic publications
Feng et al. (2015) China Exp:18–80 >uAs 48.411 FEV1 (L) Mean Diff 0.04 0.03, 0.11 Adj: age, sex, height, smoking, uCr, pack-year, alcohol, BMI, exercise.
Cross-sectional n¼2460 Out:18–80 vs. FVC (L) Mean Diff 0.00 0.08, 0.08
Male:33 <uAs 16.727 FEV1/FVC Mean Diff 0.45 0.82, 1.73
Recio-Vega et al. (2014) Mexico Exp:6–12 >uAs 181 FEV1 (%pred) Mean Diff () <p 0.02 No point estimates reported. Unadjusted. In quartiles. Reports PFT residuals, sub-analysis on
arsenic metabolites.
Cross-sectional n¼358 Out:6–12 vs. FVC (%pred) Mean Diff () >p 0.05
Male:48 <uAs 63 FEV1/FVC Mean Diff (þ) >p 0.05
Parvez et al. (2013) Bangladesh Exp:18–47 Continuous FEV1 (mL) Mean Diff 48.3 82.5, 14.1 Adj: age, sex, BMI, smoking, betel nut, education and skin lesions. Stratiﬁed by sex and smoking.
Longitudinal n¼942 Out:18–47 per μ277.2 g/g Cr FVC (mL) Mean Diff 55.2 90.5, 19.9
Male:48
Arsenical skin lesions publications
De et al. (2004) India Exp:15–50 Skin lesions FEV1 (%pred) () p¼0.025 No information on statistical analysis. Possibly regression or ANOVA.
Cross-sectional n¼159 Out:15–50 FVC (%pred) () p¼0.007
T.R
.Sanchez
et
al./
Environm
ental
R
esearch
147
(2016)
537
–555
541
Ta
b
le
2
(c
on
ti
nu
ed
)
R
ef
er
en
ce
Lo
ca
ti
o
n
A
ge
(y
rs
)
Ex
p
o
su
re
le
ve
l
O
u
tc
o
m
e
Ef
fe
ct
es
ti
m
at
e
95
%
CI
/
Co
m
m
en
ts
St
u
d
y
d
es
ig
n
Si
ze
M
al
e
(%
)
p
-V
al
u
e
M
al
e:
74
FE
V
1
/F
V
C
(þ
)
p
¼
0.
0
0
05
Pu
bl
ic
at
io
n
s
fu
rt
h
er
or
ga
n
iz
ed
by
d
at
e.
w
A
s
an
d
u
A
s
in
μg
/L
u
n
le
ss
ot
h
er
w
is
e
n
ot
ed
.A
bb
re
vi
at
io
n
s:
Ex
p
,a
ge
at
ex
p
os
u
re
;
O
u
t,
ag
e
at
ou
tc
om
e;
w
A
s,
w
at
er
ar
se
n
ic
;
u
A
s,
u
ri
n
ar
y
ar
se
n
ic
;
u
C
r,
u
ri
n
ar
y
cr
ea
ti
n
in
e;
B
M
I,
bo
d
y
m
as
s
in
d
ex
;
C
I,
C
on
ﬁ
d
en
ce
In
te
rv
al
;
PF
T,
Pu
lm
on
ar
y
Fu
n
ct
io
n
Te
st
;
FE
V
1
,F
or
ce
d
Ex
p
ir
at
or
y
V
ol
u
m
e
in
1
se
co
n
d
;
FV
C
,F
or
ce
d
V
it
al
C
ap
ac
it
y;
%
p
re
d,
p
er
ce
n
t
of
p
re
d
ic
te
d
va
lu
e;
FE
F 2
5
–
7
5
,f
or
ce
d
ex
p
ir
at
or
y
ﬂ
ow
at
25
%
–
75
%
;
PE
FR
,p
ea
k
ex
p
ir
at
or
y
ﬂ
ow
ra
te
;
(
),
n
eg
at
iv
e
ch
an
ge
;
(þ
),
p
os
it
iv
e
ch
an
ge
;
n,
st
u
d
y
si
ze
;
m
ea
n
d
if
f,
m
ea
n
d
if
fe
re
n
ce
.
T.R. Sanchez et al. / Environmental Research 147 (2016) 537–5555423.2. Lung function
Nine publications examined the relationship between InAs and
lung function (Feng et al., 2015; Recio-Vega et al., 2014; Das et al.,
2014; Parvez et al., 2013; Smith et al., 2013; Nafees et al., 2011;
Dauphine et al., 2011; von Ehrenstein et al., 2005; De et al., 2004).
Two articles did not report point estimates for the selected lung
function outcomes. De et al. (2004) and Recio-Vega et al. (2014)
only reported means, standard deviations and p-values. Table 2
shows the associations on the relationship between InAs and three
common spirometric outcomes used to measure lung function:
forced expiratory volume in one second (FEV1), forced vital capa-
city (FVC), and the ratio of FEV1 to FVC (FEV1/FVC).
3.2.1. Strength of the evidence
Spirometry is a commonly used, yet effort-dependent pul-
monary function test (PFT) and spirometry test efforts must meet
important acceptability criteria. Seven of nine publications used
American Thoracic Society (ATS) criteria (Miller et al., 2005) to
assess spirometry acceptability (Feng et al., 2015; Das et al., 2014;
Recio-Vega et al., 2014; Parvez et al., 2013; Smith et al., 2013;
Dauphine et al., 2011; Nafees et al., 2011). Spirometry outcomes
were reported in four different ways: raw measured values (mL),
predicted values using reference values derived by ethnic group (%
predicted), residual values (%predicted – measured), and disease
patterns (restrictive vs. obstructive). Although several publications
used reference values from a marginally related ethnic group to
estimate percent predicted values rather than using raw values
and adjusting for sex, age, and height, those authors noted that the
choice of reference was not critical because the purpose was to
compare InAs exposed to unexposed using the same reference
values (Feng et al., 2015; Das et al., 2014; Recio-Vega et al., 2014;
Dauphine et al., 2011; von Ehrenstein et al., 2005; De et al., 2004).
Regardless of how PFT outcomes were reported, the direction of
the association between InAs and lung function was consistent;
FVC declined with increasing InAs exposure across all nine pub-
lications. Six of the seven publications that reported point esti-
mates found a statistically signiﬁcant decrease in FEV1 and four
found a statistically signiﬁcant decrease in FVC.
Of the three articles that used ATS criteria and reported raw
values adjusted for age, sex, and height, there was a consistent
trend between increasing InAs concentration and decreasing FEV1
and FVC. Parvez et al. (2013), a longitudinal post-bronchodilator
PFT analysis among 942 Bangladeshi adults, found for every
μ118.1 g/L increase in baseline wAs, FEV1 and FVC were lowered by
46.5 mL and 53.1 mL, respectively. Results for uAs were similar.
Exposure was measured at least eight years before the outcome
was assessed; however, early life exposure history was absent.
Nafees et al. (2011), a smaller cross-sectional PFT analysis among
200 Indian adults, found that among participants exposed to
≥ μwAs 100 g/L , mean FEV1 and FVC were lowered by 154.3 mL
and 221.9 mL, respectively, compared to those exposed to
≤ μwAs 10 g/L. Although exposure assessment was based on wAs
levels measured at the time of enrollment, participants had been
using the same water source for at least one year. Among children,
the relationship between InAs and lung function was in the same
direction, yet the estimated effect size was greatly attenuated.
Smith et al. (2013), a longitudinal PFT analysis among a sample
size of 442 Bangladeshi children 7–17 years old, found for every
μ250 g/L increase in wAs concentration in utero, FEV1 and FVC
were lowered by 0.013 mL and 0.007 mL, respectively, although
results did not reach statistical signiﬁcance. Here, exposure as-
sessment was particularly strong, as children's lifetime exposure
history was reconstructed using their mother's wAs records,
where wAs ranged from ≤ μ10 g/L to > μ500 g/L.
Whereas FEV1 and FVC values are known to differ by ethnicity,
T.R. Sanchez et al. / Environmental Research 147 (2016) 537–555 543the FEV1/FVC ratio is independent of ethnic group (Quanjer et al.,
2012). Five publications reported on InAs and FEV1/FVC (Feng
et al., 2015; Parvez et al., 2013; Nafees et al., 2011; von Ehrenstein
et al., 2005). von Ehrenstein et al. (2005), a cross-sectional analysis
among 281 Indian adults, found a statistically signiﬁcant trend
between presence of arsenical skin lesions and lower FEV1/FVC
ratio among men but not among women. The FEV1/FVC ratio was
signiﬁcantly lowered by 0.025 among men with skin lesions
compared to men without arsenical skin lesions, adjusting for age,
height, and smoking (p¼0.03); they used both skin lesions and
peak wAs exposure level in the past 20 years in their analysis. Das
et al. (2014), Parvez et al. (2013) and Nafees et al. (2011) brieﬂy
describe an inverse trend between InAs and the FEV1/FVC ratio,
although results did not reach statistical signiﬁcance. Feng et al.
(2015), a cross-sectional analysis among 2360 Chinese adults,
found a positive but non-statistically signiﬁcant trend between
uAs and FEV1/FVC; however, exposure assessment was based on
one measure of uAs among a study population with low levels of
exposure (mean = μuAs 27.6 g/L).
3.2.2. Early life exposure
Few studies were able to capture all major exposure sources
from conception through adulthood. Although this is an extremely
challenging aspect for any epidemiologic study, three publications
had exposure evidence from early life (Smith et al., 2013; Dau-
phine et al., 2011; Recio-Vega et al., 2014). Early life exposure
appeared to detrimentally impact lung function levels in adult-
hood; however, the relationship between InAs and lung function
during childhood and adolescence, periods of continued lung de-
velopment, was less clear. Dauphine et al. (2011), a pilot study of
97 Chilean adults who were exposed to very high levels of wAs in
utero and in early life, found that among adults exposed to
> μwAs 800 g/L , FEV1 and FVC decreased by 224 mL and 310 mL,
respectively, compared to adults who were exposed to
≤ μwAs 250 g/L , although results were borderline signiﬁcant
(FEV1, p¼0.06, FVC, p¼0.04). Dauphine et al. (2011) had compel-
ling evidence of early life exposure history. Here, exposure history
was based on participants' long-term residence in either Antofa-
gasta or Arica, Chile. Arsenic levels in the drinking water of Arica
have always remained around μ10 g/L , whereas Antofagasta's only
source of drinking water averaged μ870 g/L during participants
ﬁrst years of life, but fell to μ150 g/L during later life. Recio-Vega
et al. (2014) examined a population of Mexican children aged 6–12
years old who were exposed to wAs between 104 and μ360 g/L
throughout their lives. Here, children's early life InAs exposure
history was assessed by restricting enrollment to participants who
had lived in the same community since the child was conceived
and used the child's current uAs level as a proxy for average life-
time exposure. There was a modest decline in %predicted FEV1 and
%predicted FVC with increasing quartile of uAs, whereas, %pre-
dicted FEV1/FVC remained unchanged. Smith et al. (2013) ex-
amined a population of Bangladeshi children aged 7–17 years old
exposed to a much wider range of wAs ( – μ )0.01 1512 g/L . There was
a slight decrease in FEV1and FVC, however the results were not
statistically signiﬁcant. Collectively, these three publications im-
plicate early life exposure to InAs as particularly hazardous to lung
function.
3.2.3. Sex differences
Three articles presented sex-stratiﬁed results (Dauphine et al.,
2011; von Ehrenstein et al., 2005; Parvez et al., 2013). In all three,
the effect estimate on InAs and lower lung function levels was
consistent and statistically signiﬁcant in men but not women. In
Parvez et al. (2013), the effect estimate for FVC was lower among
men than among women and the effect estimate for FEV1 was
statistically signiﬁcant in men only. Among women, the directionof association was consistent but not signiﬁcant. Similarly, in von
Ehrenstein et al. (2005) InAs exposure, measured using either wAs
or skin lesion status, was signiﬁcantly associated with lower FEV1
and FVC among men, but not among women. Among women, the
direction of association was again consistent but not signiﬁcant. In
Dauphine et al. (2011), early life InAs exposure was borderline
signiﬁcantly associated with lower FVC among men (p¼0.06) but
not among women. The direction of the association between InAs
and FEV1 was consistent among both men and women but was not
statistically signiﬁcant, which may be explained by the small
sample size (n¼97). Contrarily, Smith et al. (2013) did not ﬁnd
evidence of an interaction by sex ( − > )p value 0.2 . Das et al. (2014),
a publication on 834 non-smoking adult males in India, also found
a statistically signiﬁcant negative association between wAs and
both FEV1 and FVC. Thus, the sex difference ﬁndings are largely
consistent.
3.2.4. Dosimetry
Six articles examined the exposure–response trend of InAs and
lung function (Feng et al., 2015; Recio-Vega et al., 2014; Smith
et al., 2013; Parvez et al., 2013; Nafees et al., 2011; von Ehrenstein
et al., 2005) (Supplementary material). An inverse-trend was
generally strong for both FEV1 and FVC. In Nafees et al. (2011) the
statistically signiﬁcant exposure–response relationship between
individual-level wAs and decreasing FVC still held at low levels of
exposure ( < μ )wAs 100 g/L . Dauphine et al. (2011) also found an
inverse exposure–response trend, for both FEV1 and FVC. In Recio-
Vega et al. (2014) there was a decreasing trend in mean FEV1 and
FVC values with increasing quartile of unadjusted uAs, however
results did not reach statistical signiﬁcance. Parvez et al. (2013),
Nafees et al. (2011), and von Ehrenstein et al. (2005) all found an
exposure–response relationship between increasing level of wAs
and decreasing levels of FEV1 and FVC across a wide range of wAs
exposures. However, Smith et al. (2013) did not ﬁnd evidence of an
exposure–response trend at three levels of wAs ( < μ10 g/L ,
– μ10 499 g/L and > μ500 g/L), nor did Feng et al. (2015) ﬁnd evi-
dence of a dose–response trend between quartiles of uAs; how-
ever, the range of exposure was narrow.
3.3. Respiratory symptoms
More than half of the included publications in this review ex-
amined the relationship between InAs and respiratory symptoms.
Articles examined symptoms individually or combined, and re-
ported on anywhere from one to nineteen different symptom-re-
lated endpoints. Of the 18 publications on InAs and respiratory
symptoms, 11 reported a statistically signiﬁcant positive associa-
tion between InAs and at least one respiratory symptom (Das et al.,
2014; Bhattacharyya et al., 2014; Paul et al., 2013; Smith et al.,
2013; Pesola et al., 2012; Parvez et al., 2010; Ghosh et al., 2007;
Mazumder et al., 2000, 2005; Guo et al., 2003; Milton et al., 2001).
However seven did not ﬁnd a signiﬁcant association for any re-
spiratory symptom assessed (Recio-Vega et al., 2014; Farzan et al.,
2013, 2015; Amster et al., 2011; Dauphine et al., 2011; Nafees et al.,
2011; von Ehrenstein et al., 2005). Table 3 shows the associations
of this relationship among the most commonly reported end-
points, chronic cough, shortness of breath and “any respiratory
symptom.”
3.3.1. Strength of the evidence
Five articles (Recio-Vega et al., 2014; Smith et al., 2013; Dau-
phine et al., 2011; Das et al., 2014; Nafees et al., 2011) adapted
standardized respiratory symptom questionnaires from the
American Thoracic Society (Ferris, 1978), the International Study of
Asthma and Allergies in Childhood (Pearce et al., 2007), and the
British Medical Research Council (Cotes, 1987).
Table 3
Evidence table on arsenic and respiratory symptoms.
Reference Location Age (yrs) Exposure level Outcome Sex Effect estimate 95%CI/ Comments
Study design Size Male (%) p-value
−Ecological level water arsenic publications
Das et al.
(2014)
India Exp:Adults wAs:11–50 Any
symptom
Male Odds ratio 1.23 1.06, 1.44 Cough unadjusted. Dyspnea and any
symptom adj:eCO, indoor air pollu-
tion, agricultural job. Reports pre-
valence of other symptoms.
Cross-sectional n¼834 Out:Adults <wAs 10 Dry cough Male Mean Diff — <p 0.0001
Male:100 Dyspnea Male Odds ratio 1.88 1.17, 2.68
Dauphine et al.
(2011)
Chile Exp:in utero >wAs 800 Chronic
cough
All Odds ratio 1.30 0.22, 7.88 Adj:age, sex, smoking, air pollution,
edu. Showing breathlessness walking
fast/uphill.
Cross-sectional n¼97 Out:32–65 vs. Dyspnea All Odds ratio 2.53 0.68, 9.46
Male:35 <wAs 250
Ghosh et al.
(2007)
India Exp:15–70 wAs:187 Respiratory
illness
All Odds ratio 3.21 1.65, 6.26 Unadjusted. Additional results for
skin lesion status.
Cross-sectional n¼1114 Out:15–70 vs.
Male:61 wAs:9
Guo et al.
(2003)
China Exp:Adults >wAs 50 vs. Chronic
cough
All Odds ratio 12.3 5.8, 25.9 Among those without skin lesions.
Adj:age, sex, smoking, alcohol.
Cross-sectional n¼620 Out:Adults
Male:48
<wAs 10
−Individual level water arsenic publications
Smith et al.
(2013)
Bangladesh Exp:in utero >wAs 500 Coughing All Odds ratio 2.23 0.96, 5.16 Adj:age, sex, parents' edu, father's
smoking, rooms in house. Reports
other symptoms.
Longitudinal n¼650 Out:7–17 vs. Dyspnea All Odds ratio 2.7 1.01, 7.20
Male:52 <wAs 10
Pesola et al.
(2012)
Bangladesh Exp:Adults ≥wAs 50 Dyspnea All Odds ratio 1.56 1.29, 1.88 Adj:age, edu, sex, systolic BP and BMI.
Cross-sectional n¼11,746 Out:Adults vs. Male Odds ratio 2.00 1.14, 3.52
Male:43 <wAs 50 Female Odds ratio 1.51 1.23, 1.84
Nafees et al.
(2011)
Pakistan ≥Exp: 15 ≥wAs 250 Chronic
cough
All Odds ratio — >p 0.05 Reports no association with phlegm
and wheezing via logistic regression,
but no data shown.
Longitudinal n¼200 ≥Out: 15 vs. Dyspnea All Odds ratio — >p 0.05
Male:46 ≤wAs 10
Mazumder
et al.
(2000)
India < –Exp: 9 60 ≥wAs 500 Chronic
cough
Male Odds ratio 0.9 0.5, 1.7 Among non-smokers without skin
lesions. Adj:age. Also reports results
for crepitation/rhonchi, weakness.
Longitudinal n¼6862 < –Out: 9 60 vs. Female Odds ratio 1.8 1.0, 3.4
Male:41 <wAs 50 Dyspnea Male Odds ratio 1.5 0.6, 3.7
Female Odds ratio 5.2 1.9, 14.8
Urinary arsenic publications
Farzan et al.
(2015)
USA Exp:in utero Continuous Any
symptom
All Relative risk 1.1 1.0, 1.5 Adj:mom's age, mom's smoking, sex,
birth weight, GA, breastfed, daycare,
parity.
Longitudinal n¼412 Out:12 mo median¼3.8 Cough All Relative risk 1.1 1.0, 1.2
Male:46 Dyspnea All Relative risk 1.1 0.8, 1.5
Recio-Vega
et al.
(2014)
Mexico Exp:6–12 >uAs 181 Chronic
cough
All Odds ratio 1.25 >p 0.05 In quartiles. OR calculated for review.
Unadjusted.
Cross-sectional n¼358 Out:6–12 vs. Dyspnea All Odds ratio 1.00 >p 0.05
Male:48 <uAs 63
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Table 3 (continued )
Reference Location Age (yrs) Exposure level Outcome Sex Effect estimate 95%CI/ Comments
Study design Size Male (%) p-value
Farzan et al.
(2013)
USA Exp:in utero Continuous Any
symptom
All Relative risk 1.1 0.8, 1.6 Adj:mom's age, GA, sex, birth wgt,
parity, breastfed, daycare.
Longitudinal n¼214 Out:4 mo median¼3.7
Male:46
Amster et al.
(2011)
USA ≥Exp: 20 >uAs 17.23 Chronic
cough
All Odds ratio 0.49 0.16, 1.50 In quintiles. Adj:age, sex, race, edu,
BMI, serum cotinine, mercury, uCr,
uAsB.
Longitudinal n¼2687 ≥Out: 20 vs.
Male:49 >uAs 3.52
Parvez et al.
(2010)
Bangladesh Exp:Adults > μuAs 406 g/g Cr Chronic
cough
All Hazard ratio 1.51 1.21, 1.87 In quintiles. Adj:age, sex, BMI, smok-
ing, edu, skin lesions, well-switching.
Longitudinal n¼11,746 Out:Adults vs. Dyspnea All Hazard ratio 1.27 1.05, 1.53
Male:43 ≤uAs 90
Arsenical skin lesions publications
Bhattacharyya
et al.
(2014)
India ≥Exp: 15 Skin lesions Chronic
cough
All Odds ratio 3.23 1.72, 6.07 Unadjusted
Cross-sectional n¼390 ≥Out: 15 Dyspnea All Odds ratio 1.76 0.84, 3.71
Male:62
Paul et al.
(2013)
India < –Exp: 20 60 Skin lesions Respiratory
problems
All Odds ratio 11.45 5.0, 25.9 Outcomes from 2010 to 2011.
Cross-sectional n¼360 < –Out: 20 60
Male:50
Mazumder
et al.
(2005)
India Exp:Adults Skin lesions Cough All Odds ratio 3.2 1.7,6.1 Unadjusted
Cross-sectional n¼258 Out:Adults
Male:30
von Ehrenstein
et al.
(2005)
India ≥Exp: 20 Skin lesions Chronic
cough
Male Odds ratio 1.9 0.3, 11.4 Among non-smokers. Adjusted for
age. Breathlessness when walking
fast/uphill. Also reports results
among smoking men.
Cross-sectional n¼281 ≥Out: 20 Female Odds ratio 2.2 0.8, 6.2
Dyspnea Male Odds ratio 2.3 0.7, 7.6
Male:86 Female Odds ratio 1.2 0.5, 2.9
Milton et al.
(2001)
Bangladesh Exp:5–51þ Skin lesions Chronic
cough
All Risk ratio 2.9 1.5, 5.3 Also reports on chronic respiratory
distress and sex stratiﬁed.
Cross-sectional n¼218 Out:5–51þ
Male:41
Publications further organized by date. wAs and uAs in μg/L unless otherwise noted. Abbreviations: Exp, age at exposure; Out, age at outcome; n, study size; Mean Diff, mean
difference; adj, adjusted for; edu, education; eCO, exhaled carbon monoxide; GA, gestational age; uCr, urinary creatinine; and uAsB, urinary arsenobetaine. Acute respiratory
symptoms include: cough, difﬁculty breathing, and wheeze.
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respiratory symptoms into one inclusive variable (Farzan et al.,
2013, 2015; Das et al., 2014; Paul et al., 2013; Ghosh et al., 2007).
Although these publications included slightly different combina-
tions of symptoms, the positive association between InAs and “any
respiratory symptom” was consistent and statistically signiﬁcant.
Paul et al. (2013), a cross-sectional analysis repeated at two time
points among Indian adults, found InAs-exposed participants had
signiﬁcantly higher odds of respiratory symptoms (deﬁned as
persistent cough, thoracic sounds, throat irritation, loss of breath,
and hoarseness) compared to unexposed (unadjusted OR¼11.45,95% CI¼5.04, 25.97). Here, exposure was primarily assessed by
presence or absence of skin lesions and conﬁrmed by wAs and uAs
levels among a subset of participants. Ghosh et al. (2007), also
examined the same set of respiratory symptoms in a group of 1114
Indians ranging from 15 to 70 years old. Exposure grouping was
assessed by location of residence, and conﬁrmed wAs and uAs
level among some participants. Ghosh et al. (2007) found exposed
participants had greater odds of respiratory illness compared to
unexposed, regardless of presence of skin lesions and after ad-
justing for age, sex, and smoking. Das et al. (2014), a cross-sec-
tional analysis of 834 adult non-smoking men in India, found the
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cough with phlegm, wheeze, chest discomfort, and breathlessness
on exertion) among InAs exposed males ( – μ )11 50 g/L was 1.23
higher compared to unexposed ( < μ )10 g/L , after adjusting for
exhaled CO, indoor air pollution, and agricultural occupation. Ex-
posure assessment was based on residing in either an InAs-en-
demic village for the past 10 years or InAs-free village for the past
5 years.
Urinary arsenic may be a more important marker of exposure
when InAs levels in drinking water are low, as urinary levels re-
ﬂect all ingestion pathways. Notably, Farzan et al. (2013, 2015), two
publications on same study population of US infants exposed to
InAs in utero, expressed the importance of dietary InAs exposure in
their study population and used maternal uAs concentrations
during pregnancy to assess in utero exposure. Both publications
found a borderline signiﬁcant positive association between InAs
and any respiratory symptom (cough, difﬁculty breathing, and
wheeze). Compared to the earlier publication, Farzan et al. (2015)
had double the sample size and two additional follow-up periods
(8 months and 12 months).
Cough. Fourteen publications examined the relationship be-
tween InAs and cough (Farzan et al., 2015; Bhattacharyya et al.,
2014; Das et al., 2014; Recio-Vega et al., 2014; Smith et al., 2013;
Amster et al., 2011; Dauphine et al., 2011; Nafees et al., 2011; Parvez
et al., 2010; Mazumder et al., 2000, 2005; von Ehrenstein et al.,
2005; Guo et al., 2003; Milton et al., 2001). Publications commonly
categorized cough by productive/non-productive and severity/fre-
quency. Overall, InAs was signiﬁcantly positively associated with
coughing symptoms in six of the fourteen publications; however,
not every publication adjusted for potential confounders, including
age, sex and smoking. Of the articles that found a statistically sig-
niﬁcant positive relationship between InAs exposure and cough,
only two sufﬁciently adjusted for important potential confounders
(Parvez et al., 2010; Guo et al., 2003). In Parvez et al. (2010) over
11,000 Bangaldeshi adults were followed over four years. Exposure
was measured at the individual level, using both well wAs and uAs.
Parvez et al. (2010) found the hazard ratio for incident chronic
cough among those with the highest quartile of wAs ( > μ )178 g/L
was signiﬁcantly greater than those in the lowest quartile of
exposure ( ≤ μ )10 g/L after adjusting for age, sex, BMI, smoking,
education, skin lesion status and well-switching status. While ex-
posure history did not extend back to early life, this publication did
capture all possible exposure routes, as the associationwas similarly
consistent and signiﬁcant for uAs. Guo et al. (2003) described a
cross-sectional analysis among 620 Chinese adults. Exposure as-
sessment was based on area of residence, with a conﬁrmatory wAs
testing on a subset of 25% and 10% of individuals in InAs exposed
and unexposed villages, respectively. They reported that partici-
pants from the InAs exposed village had 12.8 times the odds of
cough compared to those in the unexposed village, after adjusting
for sex, age, smoking, and alcohol consumption (95% CI¼5.8, 25.9).
Although the four other publications that controlled for po-
tential confounders did not ﬁnd a statistically signiﬁcant re-
lationship among InAs and cough (Farzan et al., 2015; Smith et al.,
2013; Dauphine et al., 2011; Amster et al., 2011) the direction of
the association was consistently positive in all but one publication.
Amster et al. (2011) cross-sectionally examined the relationship
between InAs and self-reported chronic cough among 2687 US
adult participants in the 2003–2004 and 2005–2005 NHANES
cohorts. Curiously, they found participants in the highest quartile
of uAs ( > μ )17.23 g/L had lower odds of chronic cough (deﬁned as
having a cough for three consecutive months or more throughout
the year) compared to participants in the lowest quartile of uAs
( < μ )3.52 g/L , after adjusting for sex, age, race/ethnicity, education,
serum cotinine, serum mercury, urinary creatinine and arsenobe-
taine (OR¼0.49, 95% CI¼0.16,1.50); however, they relied on asingle measure of uAs as a proxy for past InAs exposure. Urinary
arsenic, while a standard marker for recent exposure, is a weak
maker of long term exposure. Farzan et al. (2015), also examining a
US population, found pre-natal uAs exposure was marginally as-
sociated with an increased risk of cough (deﬁned as lasting two or
more days during in the ﬁrst year of life) among infants (RR¼1.1,
95% CI¼1.0, 1.2). Smith et al. (2013), examined three different
variables related to cough in the last 12 months: coughing when
not having a cold, coughing when having a cold, and dry cough.
The odds of coughing when not having a cold among children
exposed to higher levels of wAs in utero ( ≥ μ )500 g/L was 2.23
times that of children exposed to < μwAs 10 g/L , after adjusting for
age, sex, mother's education, father's education and smoking sta-
tus, and number of rooms in the house (95% CI¼0.96, 5.16).
Dauphine et al. (2011) examined the prevalence of chronic cough
among Chilean adults exposed to very high levels early in life. The
odds of chronic cough among those exposed to > μwAs 800 g/L
before age 10 was 1.3 times the odds among those exposed to
< μwAs 250 g/L , after adjusting for age, sex, smoking, childhood
secondhand smoke, fuel type used in childhood home, occupa-
tional air pollution and education. Even though exposure was as-
sessed ecologically, exposure history in this population was very
strong (see Section 3.2.2.).
Dyspnea. Eleven publications examined InAs and a symptom
concerning shortness or breath/dyspnea/trouble breathing (Farzan
et al., 2015; Bhattacharyya et al., 2014; Das et al., 2014; Recio-Vega
et al., 2014; Smith et al., 2013; Pesola et al., 2012; Dauphine et al.,
2011; Nafees et al., 2011; Parvez et al., 2010; von Ehrenstein et al.,
2005; Mazumder et al., 2000). Overall, the direction of the asso-
ciation was consistently positive for all but one publication (Recio-
Vega et al., 2014). Half of the publications used standardized
questionnaires and graded scales of dyspnea based on different
circumstances in which it arose (Das et al., 2014; Recio-Vega et al.,
2014; Smith et al., 2013; Dauphine et al., 2011; von Ehrenstein
et al., 2005). Of the ﬁve articles that adjusted for potential con-
founders, including sex, age, and smoking status, four found a
signiﬁcant positive relationship between InAs and dyspnea (Farzan
et al., 2015; Smith et al., 2013; Pesola et al., 2012; Dauphine et al.,
2011; Parvez et al., 2010). Smith et al. (2013) and Dauphine et al.
(2011) found participants exposed to high levels of wAs had
greater odds of breathlessness (and at multiple degrees of sever-
ity); both publications also had strong exposure assessments. Si-
milarly, Parvez et al. (2010) and Pesola et al. (2012) found sig-
niﬁcant, positive associations. These two publications reported
dyspnea ﬁndings from the same study population, the Health Ef-
fects of Arsenic Longitudinal Study (HEALS cohort), but Pesola
et al. (2012) examined HEALS baseline symptoms, whereas Parvez
et al. (2010) excluded those with respiratory symptoms at baseline
and examined symptom incidence at HEALS follow-up visits.
Mazumder et al. (2000, 2005) and von Ehrenstein et al. (2005)
also reported ﬁndings from the same source population of 7683
participants in a cross-sectional study originally conducted from
1995 to 1996 in 24-South Parganas, West Bengal, India. Here, every
member of the household who was present at the time of inter-
view was invited to participate, regardless of age. Mazumder et al.
(2000) reported ﬁndings from the ﬁrst iteration of this study,
among 6864 non-smokers. They found age-adjusted prevalence of
cough and dyspnea increased with increasing wAs level, particu-
larly among those with arsenical skin lesions; however, ﬁndings
were not adjusted for other confounders. von Ehrenstein et al.
(2005) reported ﬁndings from an interview conducted between
April 1998 and January 2000. Here, smokers were included, par-
ticipation was restricted to those 20 years or older, and skin lesion
status was used a their primary exposure marker. They found
among their 287 participants, odds for respiratory symptoms as-
sociated with arsenical skin lesion status was generally elevated in
Table 4
Evidence table on InAs and acute respiratory tract infections.
Reference Location Age Exposure level Outcome Effect estimate 95% CI Comments
Study design Size Male (%)
Individual-level water arsenic publications
Smith et al.
(2013)
Bangladesh Exp:in utero ≥wAs 500 Pneumonia Odds ratio 1.43 0.73, 2.65 Adj:age, gender, parents' edu, father's
smoking and rooms in house.
Longitudinal n¼650 Out:7–17 yrs vs.
Male:52 <wAs 10
Maternal urinary arsenic publications
Farzan et al.
(2015)
USA Exp:in utero Continuous ≥LRTI 2 days Rel Risk 1.1 0.9,1.4 Adj:maternal age, maternal smoking,
infant sex, gest age, birth weight,
breast feeding, day care and parity.
Longitudinal n¼412 Out:12 mo median¼3.8 LRTI þ
medication
Rel Risk 1.2 1.0,1.5
Male:46
George et al.
(2015)
Bangladesh Exp:1–59 mo ≥uAs 51 Pneumonia Odds ratio 2.04 0.92, 4.51 By quartile at hospital admission.
Adj:weight-for-height, breastfeeding,
age, paternal edu, uCr. Also at con-
valescents and severity.
Case-control Cases¼153 Out:1–59 mo vs.
Control¼296 Cases:43 Ctrls:46 <uAs 6
Recio-Vega
et al. (2014)
Mexico Exp:6–12 ≥uAs 181 Bronchiolitis (þ) — <p 0.05 By quartile. unadjusted. No descrip-
tion of statistical analysis given
Cross-sectional n¼358 Out:6–12 vs.
Male:48 <uAs 63
Farzan et al.
(2013)
USA Exp:in utero Continuous ≥1 LRTI Rel Risk 1.4 0.7, 3.1 Adj:maternal age, infant sex, gest age,
birth weight, breast feeding, day care
and parity.
Longitudinal n¼214 Out:4mo Median¼3.7 LRTI þ
medication
Rel Risk 3.3 1.2, 9.0
Male:46
Rahman et al.
(2011)
Bangladesh Exp:in utero ≥uAs 269 LRTI Rel Risk 1.74 1.41, 2.14 uAs@gw30. By quintiles. Adj:mo-
ther's edu, asset index, parity, BMI,
gest age, sex. Reports severe LRTI and
dose–response.
Longitudinal 115,850 Out:12mo vs.
prsn-days Male:52 <uAs 36
Raqib et al.
(2009)
Bangladesh Exp:in utero Continuous ARI Mean Diff 0.004 0.001,
0.006
uAs@gw30. Adj:infants BAZ, mothers
BMI, SES, gender. Reports uAs@ gw6-
10.
Longitudinal n¼140 Out:6–12 mo
Male:54 Median¼64.7
Publications further organized by date. wAs and uAs in μg/L unless otherwise noted. Abbreviations: ARI, acute respiratory infection; LRTI, lower respiratory tract infection;
BAZ, BMI adjusted Z-score; Rel Risk, relative risk; Mean Diff, mean difference; Exp, age at exposure; Out, age at outcome; uAs@gw30, urinary arsenic at gestational week 30;
gest age, gestational age; yrs, years; mo, months; SES, socio-economic status; uCr, urinary creatinine; and (þ), positive trend.
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ported in Mazumder et al. (2005) came from an interview be-
tween 2001 and 2003. They found higher odds of chronic cough
(deﬁned as self-reported cough for ≥3 months per year for at least
two years) among participants with arsenical skin lesions com-
pared to those without lesions; however, chronic cough was a
secondary analysis and the ﬁnding was not adjusted for important
potential confounders, including age, sex, and smoking status.
3.3.2. Early life exposure
Three of the four articles which examined in utero exposure
found a statistically signiﬁcant increase in respiratory symptoms
among infants (Farzan et al., 2015), children (Smith et al., 2013),
and adults (Dauphine et al., 2011). Among 4 month-old infants
exposed to InAs in utero ( = – μ )uAs range 0.5 58.3 g/L , there was an
increased risk of acute respiratory symptoms treated with a pre-
scription medication per one natural log unit increase in uAsexposure (RR¼1.2, 95% CI¼1.0, 1.5) (Farzan et al., 2015). In this US
population with low wAs exposure levels, the authors noted the
importance of dietary InAs exposure and thus used maternal uAs,
which reﬂects all ingestion pathways, as a proxy for infants' in
utero exposure. Among children, 7–17 years old, those exposed to
wAs in utero ranging from μ10 g/L to ≥ μ600 g/L , had increased
odds of wheeze, asthma, coughing, and shortness of breath com-
pared to children who were exposed to < μwAs 10 g/L in utero and
throughout childhood (Smith et al., 2013). Among adults, 32–65
years old, those exposed to wAs levels between 250 and μ800 g/L
in early life, had increased odds in breathlessness when walking at
group pace (OR¼5.94, 95% CI¼1.36, 26.0) compared to adults who
were exposed to < μ250 g/L in early life (Dauphine et al., 2011).
3.3.3. Sex differences
Five articles either mentioned or presented sex-stratiﬁed data
on respiratory symptom effects (Pesola et al., 2012; Parvez et al.,
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et al., 2000). There was some evidence that the odds of cough was
greater for females than for males and odds of dyspnea was
greater for males; however, evidence was not consistent. Pesola
et al. (2012) found the odds ratio for dyspnea, among non-smo-
kers, was greater for males than for females. von Ehrenstein et al.
(2005) also found the odds ratio for dyspnea was greater for males
than for females but found the odds ratio for cough was greater for
females than for males; however, results for either symptom in
either sex did not reach statistical signiﬁcance. Alternatively, Ma-
zumder et al. (2000) found the age-adjusted odds ratio for both
dyspnea and cough was greater for females than for males. Milton
et al. (2001) found the unadjusted odds ratio for chronic cough
was greater for females than for males. Notably, Parvez et al.
(2010) mentioned that there was not an appreciable difference
between sex and thus did not stratify results.
3.3.4. Dosimetry
Five articles examined the exposure–response relationship
between InAs and respiratory symptoms, with generally strong
evidence of a positive trend (Recio-Vega et al., 2014; Smith et al.,
2013; Pesola et al., 2012; Parvez et al., 2010; Mazumder et al.,
2000). Pesola et al. (2012) found a statistically signiﬁcant trend
between increasing wAs quintile and increasing odds of dyspnea,
even at lower levels of wAs exposure ( – μ39 91 g/L vs. ≤ μ7 g/L).
Parvez et al. (2010) also reported an exposure–response trend
between increasing wAs quintiles and increasing risk of chronic
cough incidence ( = < > μ )wAs range 7 to 178 g/L . Interestingly,
the highest risk for dyspnea was among those with wAs between
40 and μ90 g/L . Recio-Vega et al. (2014) presented tabular results
between uAs quartiles and several respiratory symptoms,
but a modest trend was only seemingly apparent for frequent
cough. Mazumder et al. (2000) also presented evidence of
a statistically signiﬁcant exposure–response trend between
wAs and both increasing shortness of breath and cough
( = < > μ )wAs range 50 to 800 g/L ; however, the highest pre-
valence for dyspnea was among those with wAs between 200 and
μ499 g/L . Smith et al. (2013) also examined the exposure–response
trends for a subset of respiratory symptoms with an adjusted
>OR 2.0 in bivariate analysis (in utero wAs range¼10 to
> μ600 g/L). There was a consistent trend between increasing bin of
InAs exposure and increasing odds of six respiratory symptoms:
wheezing ever, asthma, coughing when not having a cold, short-
ness of breath when walking fast or climbing, shortness of breath
when walking on level ground, and wheezing when not having a
cold. Interestingly, for most symptoms the highest odds was
among those with in utero wAs between 400 and μ599 g/L .
3.4. Acute respiratory tract infections
There were seven publications on InAs and respiratory tract
infections (George et al., 2015; Farzan et al., 2013, 2015; Recio-
Vega et al., 2014; Smith et al., 2013; Rahman et al., 2011; Raqib
et al., 2009). Overall, there was a modest positive association be-
tween InAs exposure and frequency and/or severity of respiratory
tract infections (RTI) (Table 4). Articles examined infections com-
bined and individually, including pneumonia and bronchiolitis.
3.4.1. Strength of the evidence
Recio-Vega et al. (2014) reported a statistically signiﬁcant in-
crease in bronchiolitis among children in the highest quartile of
uAs ( > μ )181 g/L compared to children in the lowest quartiles of
uAs ( < μ )63 g/L ; however, only a p-value was reported and it was
unclear whether results were adjusted for potential confounders.
George et al. (2015), a case-control analysis, examined the asso-
ciation between physician-diagnosed WHO-deﬁned pneumoniaand uAs levels. There was a positive relationship between uAs
level at hospital admission and odds of pneumonia, but only in-
fants with uAs in the third quartile ( – μ )17 50.9 g/L had signiﬁcantly
greater odds of pneumonia than infants in the lowest quartile of
uAs ( < μ )6 g/L , after adjusting for urinary creatinine, weight for
height, breastfeeding, paternal education, age, and number of
people living in the household (OR¼2.11, 95% CI¼1.10,4.34). Ex-
posure assessment was restricted to uAs either at time of hospi-
talization or during recovery and did not have a record of past
exposure among cases, whereas uAs was measured once at time of
enrollment among controls. Smith et al. (2013) also presented
some data on self-reported pneumonia. The article reported a
statistically signiﬁcant increase in pneumonia among children
exposed to wAs – μ10 499 g/L compared to children exposed to
< μ10 g/L , after adjusting for potential confounders, but the asso-
ciation was not statistically signiﬁcant at higher exposure levels
> μwAs 500 g/L (OR¼1.43, p-value¼0.13).
As noted in Section 3.3.1, Farzan et al. (2013, 2015) examined
the same study population in the USA. Both analyses found in
utero InAs exposure was associated with a higher risk of infection
during the ﬁrst year of life. Farzan et al. (2013) found an increased
risk of “lower RTI (LRTI) treated with a prescription medication”
(deﬁned by RSV, pertussis, bronchitis, bronchiolitis, pneumonia)
among 4 month old infants exposed in utero.
Articles by Rahman et al. (2011) and Raqib et al. (2009) were
both from the same study region in Bangladesh. Whereas Raqib
et al. (2009) had a much smaller study population (N¼140),
Rahman et al. (2011) studied 115,850 person-years of observation
time from 1552 participants. Raqib et al. (2009) found an increase
in acute respiratory infection (deﬁned by cough, fever or shaking
chills, and fast breathing, difﬁculty breathing or chest retractions)
with increasing in utero uAs level among infants 6–12 months old.
Rahman et al. (2011) similarly found an increased relative risk of
LRTI (deﬁned by cough and/or difﬁculty breathing combined with
rapid respiration) with increasing maternal uAs.
3.4.2. Early life exposure
Four publications used maternal uAs as a marker of gestational
exposure but did not have a measure of the child's post-natal ex-
posure (Farzan et al., 2013, 2015; Rahman et al., 2011; Raqib et al.,
2009). Farzan et al. (2015) found that associations with InAs exposure
during pregnancy were strong for infections at 4 months of age and
weaker for infections at 8 or 12 months of age. Whereas Rahman
et al. (2011) found that associations with InAs exposure during
pregnancy were stronger for LRTI at 6–11 months of age than for LRTI
at 0–5 months. Smith et al. (2013) reported greater odds of pneu-
monia only among older children 7–17 years old who were pre-
natally exposed ( – μ )wAs 10 499 g/L compared with never exposed.
3.4.3. Sex differences
Raqib et al. (2009) found the correlation between in utero InAs
and acute respiratory infections among boys (r¼0.72, p¼0.0001)
was signiﬁcantly greater than the correlation among girls (r¼0.38,
p¼0.32).
3.4.4. Dosimetry
Three publications examined RTIs at lower levels of exposure
and report modest ﬁndings. Rahman et al. (2011) found a statis-
tically signiﬁcant trend between increasing quintile of mothers'
uAs and both increasing risk of LRTI and severe LRTI. Urinary ar-
senic exposure levels in Rahman et al. (2011) ranged from 6 to
μ977 g/L , and even at the lowest quintiles of in utero exposure
( – μ39 64 g/L vs. < μ39 g/L) the association remained signiﬁcant
(RR¼1.28, p¼0.03). Arsenic exposure levels in Farzan et al.
(2013, 2015) were much lower (mean = μuAs 3.7 g/L , wAs
= – μrange 0.01 67.5 g/L), and had smaller effect estimates (RR¼1.1,
Table 5
Evidence table on InAs and chronic non-malignant lung disease.
Reference Location Age (yrs) Exposure level Outcome Effect estimate 95% CI Comments
Study design Size Male (%)
−Ecological level water arsenic publications
Dauphine et al.
(2011)
Chile Exp:in
utero
>wAs 800 Chronic bronchitis Odds ratio 1.02 0.09, 11.6 Unadjusted
Cross-sectional n¼97 Out:32–65 vs.
Male:35 <wAs 250
Urinary arsenic publications
Amster et al. (2011) USA ≥Exp: 20 >uAs 17.23 Chronic bronchitis Odds ratio 0.77 0.24, 2.51 By quintile. Adj:age, gender,
race, edu, BMI, serum cotinine
and Hg, urinary creatinine and
arsenobetaine.
Cross-sectional n¼2687 ≥Out: 20 vs. Emphysema Odds ratio 1.29 0.17, 9.82
Male:49 <uAs 3.52
Arsenical skin lesions publications
Bhattacharyya et al.
(2014)
India ≥Exp: 15 Skin lesions Pulmonary artery
dilatation
Odds ratio 6.98 2.3, 16.5 Unadjusted. Sex-stratiﬁed re-
sults also reported.
Cross-sectional n¼390 Out:≥15
Male:62
Mazumder et al.
(2005)
India Exp:Adults Skin lesions Bronchiectasis Odds ratio 10.0 2.7, 37.0 Adj:age, sex, smoking, and self-
reported tuberculosis.
Cross-sectional n¼258 Out:Adults
Male:30
von Ehrenstein et al.
(2005)
India ≥Exp: 20 Skin lesions Chronic bronchitis Odds ratio 0.3 0.03, 2.7 Nonsmoker women shown.
Also results on male smokers.
Cross-sectional n¼287 Out:≥20
Male:62
Milton et al. (2001) India Exp:5–51þ Skin lesions Chronic bronchitis Risk ratio 3.0 1.6, 5.3 Among non-smokers. Adj:sex.
Sex-stratiﬁed results also
reported.
Cross-sectional n¼218 Out:5–51þ
Male:41
Publications further organized by date. wAs and uAs in μg/L unless otherwise noted. Abbreviations:Exp, age at exposure; Out, age at outcome; uCr, urinary creatinine; and
Hg, mercury.
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range in uAs levels in George et al. (2015) ranged from 4.5 to
μ41 g/L among controls, and from 8.0 to μ64 g/L among cases.
George et al. (2015) found odds of pneumonia was greatest among
the third quartile of uAs. Although Smith et al. (2013) did not
formally test the exposure–response relationship between pre-
natal wAs exposure and pneumonia, the article did present some
results from multiple logistic regression at two levels of wAs
( – μ10 499 g/L and ≥ μ500 g/L) but a trend was not apparent.
3.5. Chronic non-malignant lung disease
Six publications examined the relationship between InAs and
chronic non-malignant lung disease (Table 5). Few articles in this
category examined the same disease outcome, and thus the re-
lationship between InAs and speciﬁc chronic non-malignant lung
diseases in adults was unclear. The speciﬁc disease outcomes
presented here include pulmonary artery dilatation, bronch-
iectasis, emphysema, and chronic bronchitis.
3.5.1. Strength of the evidence
Chronic bronchitis. Four publications examined the relationship
between InAs and chronic bronchitis (Amster et al., 2011; Dau-
phine et al., 2011; Milton et al., 2001; von Ehrenstein et al., 2005).
Milton et al. (2001), a cross-sectional analysis among 218 non-
smoking Indian adults, found participants with arsenical skin le-
sions had greater risk of chronic bronchitis (deﬁned as sputumproduction on most days for at least three consecutive months for
more than two successive years with the presence of rhonchi and/
or crepitation) compared to those without skin lesions, after ad-
justing for sex but not age (OR¼3.0, 95% CI¼1.6, 5.3). Exposure
assessment in this analysis was multi-faceted. Exposed partici-
pants came from one of three InAs affected villages and had
physician-conﬁrmed arsenicosis, whereas unexposed participants
were randomly recruited from a village without InAs-con-
taminated wells and had no evidence of arsenicosis. von Ehren-
stein et al. (2005), a cross-sectional analysis among a total of 287
Indian adults, found that among smoking males, those with skin
lesions had greater age-adjusted odds of chronic bronchitis (de-
ﬁned as cough and phlegm for at least 12 months) compared to
those without skin lesions, however results did not reach statis-
tical signiﬁcance (OR¼2.0, 95% CI¼0.7, 5.8). Dauphine et al. (2011),
a cross-sectional analysis among 97 Chilean adults (see Section
3.2.2), also found a modest association (OR¼1.02, 95% CI¼0.09,
11.6), but only three total cases of chronic bronchitis were re-
ported. Alternatively, Amster et al. (2011), a cross-sectional ana-
lysis among 5365 US adults, found those in the highest quartile of
uAs ( > μ )17.23 g/L had lower odds of self-reported chronic bron-
chitis compared to those in the lowest quartile ( < μ )3.52 g/L ;
however, results did not reach statistical signiﬁcance even after
adjusting for sex, age, race, education, serum cotinine, arsenobe-
taine and urinary creatinine (OR¼0.77, 95% CI¼0.24, 2.51). The
direction of the association in Amster et al. (2011) is inconsistent
with the other three publications on chronic bronchitis. Despite its
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Amster et al. (2011) may be related to incomplete history of prior
InAs exposure. Although uAs is a good biomarker of recent ex-
posure, it does not adequately reﬂect long-term InAs exposure.
Further, the range of exposure in Amster et al. (2011) was also
narrow (mean exposed = μuAs 172.3 g/L , mean unexposed
= μuAs 3.52 g/L).
Other chronic non-malignant lung diseases. Amster et al. (2011)
also reported greater odds of self-reported emphysema among
those with the highest quartile of uAs compared to those in the
lowest quartile, although results did not reach statistical sig-
niﬁcance (OR¼1.29, 95% CI¼0.17, 9.82). Mazumder et al. (2005)
found a statistically signiﬁcant increase in bronchiectasis (de-
termined by high-resolution computed tomography) among those
with skin lesions. One of the major limitations of this publication
was that only participants with self-reported cough were given a
referral for bronchiectasis testing and of those who were referred,
those who underwent CT-testing differed by exposure group.
Overall, 25% of exposed (27/108) and 7% of unexposed (11/150)
underwent CT-test. Bhattacharyya et al. (2014) found a statistically
signiﬁcant increase in pulmonary artery dilatation (also de-
termined by high-resolution computed tomography) among those
with skin lesions; however, ﬁndings were not adjusted for po-
tential confounders, including sex and smoking status.
3.5.2. Early life exposure
Dauphine et al. (2011) was the only publication in this category
with exposure assessment in early life; however there were
not enough cases of chronic bronchitis to adjust for potential
confounders.
3.5.3. Sex differences
Four publications stratiﬁed their results by sex (Bhattacharyya
et al., 2014; Mazumder et al., 2005; von Ehrenstein et al., 2005;
Milton et al., 2001). In general, associations among males seemed to
be stronger than associations among females. Bhattacharyya et al.
(2014) found the association between InAs exposure and pulmonary
artery dilation was stronger in men (OR¼7.53, 95% CI¼2.15, 25.82)
than inwomen (OR¼4.49, 95% CI¼1.11–23.53), results were adjusted
for age but not smoking. Mazumder et al. (2005) also found the as-
sociation between InAs exposure and bronchiectasis was stronger in
men (OR¼13.0, 95% CI¼2.6, 62) than in women (OR¼6.1, 95%
CI¼0.6, 62), after adjusting for age, smoking, and self-reported tu-
berculosis history. von Ehrenstein et al. (2005) reported ﬁndings
among smoking males and non-smoking females, but not among
non-smoking males. Whereas the direction of association between
InAs and chronic bronchitis was again positive among smoking men
(OR¼2.0, 95% CI¼0.7, 5.8), there was a negative association among
non-smoking females (OR¼0.3, 95% CI¼0.03, 2.7), although neither
ﬁnding reached statistical signiﬁcance. Alternatively Milton et al.
(2001) found the association between InAs exposure and chronic
bronchitis among non-smokers was much stronger in women
(OR¼10.3, 95% CI¼2.4, 43.1) than in men (OR¼1.6, 95% CI¼0.8, 3.1),
although results were not adjusted for age.
3.5.4. Dosimetry
None of the six article in this category examined dosimetry.
3.6. Non-malignant lung disease mortality
Five publications examined InAs and non-malignant lung dis-
ease mortality (Argos et al., 2014; Smith et al., 1998, 2006, 2011;
Tsai et al., 1999) (Table 6). Publications studied several relevant
causes of death, including bronchiectasis, COPD, bronchitis, em-
physema, pulmonary tuberculosis, and non-malignant lung dis-
ease (a combination of primary pulmonary hypertension anddiseases of the respiratory system).
3.6.1. Strength of the evidence
Overall, there was strong evidence between InAs exposure and
increased non-malignant lung disease mortality. However, there
was also a moderate risk of outcome misclassiﬁcation, as all
publications were based on death certiﬁcates or verbal autopsy,
which may be subjectively decided. Tsai et al. (1999), an ecological
analysis in Taiwan, found signiﬁcantly increased bronchitis mor-
tality rates between 1971 and 1994, however it is possible that the
ﬁndings may have been inﬂuenced by exposure misclassiﬁcation,
as there was greater variability of InAs in the exposure area. Argos
et al. (2014), a longitudinal analysis of over 26,000 adults with
over 220,000 person-years of follow-up time, also found greater
hazards of non-malignant lung disease mortality among partici-
pants with the highest tertile of creatinine-adjusted uAs
( ≥ μ )332 g/g Cr compared to those with the lowest tertile
( < μ )132.5 g/g Cr , after adjusting for important potential con-
founders, including sex, age, BMI, education, and smoking
(HR¼1.75, 95% CI¼1.15, 2.66). Results were similar for wAs. Al-
though Argos et al. (2014) did not capture early life InAs exposure,
results from exposed populations in Antofagasta, Chile, with
known lifetime exposure, show comparable ﬁndings. The 1998,
2006 and 2011 publications of Smith et al. studied the same region
in Chile. Arsenic exposure was particularly well documented in
this time period for Antofagasta, Chile, so there was little risk of
exposure misclassiﬁcation in the three Chilean ecological pub-
lications. Smith et al. (1998, 2006) reported variations on one
outcome of interest to this review, COPD. While Smith et al. (1998)
found no overall increase in deaths from COPD (SMR¼1.0, 95%
CI¼0.8, 1.1), the analysis covered a shorter time period, 1989–1993
and included mortality at all ages. Smith et al. (2006) subsequently
examined mortality from 1989–2000, focused on subjects be-
tween the ages 30 and 49, and subdivided COPD deaths into two
categories, bronchiectasis and “other COPD.” They found sig-
niﬁcantly increased SMRs for COPD (SMR¼7.6, 95% CI¼3, 15.6)
and bronchiectasis (SMR¼46.2, 95% CI¼21.1, 87.7), especially
among those exposed in utero during peak InAs exposure. Inter-
estingly, Smith et al. (2011) further explored the time trend and
interplay between the respiratory and immune systems by esti-
mating mortality rate ratios of pulmonary tuberculosis between
two regions in Chile. This analysis showed that tuberculosis mor-
tality rate ratios started to increase 10 years after high InAs
exposure.
3.6.2. Early life exposure
Three articles examined whether high InAs exposure in utero and
during childhood was associated with increased mortality in adult-
hood (Smith et al., 1998, 2006, 2011). All three publications came
from Chile. In these articles, mortality was most pronounced when
exposure occurred in utero and at very high levels. People exposed
early in life died of bronchiectasis, COPD, and pulmonary tuberculosis
at a younger age and at greater numbers compared to those exposed
to InAs only in adulthood or later in childhood. Among these three
ecological investigations, when exposure was not restricted by age, as
in Smith et al. (1998) and Tsai et al. (1999), the relationship between
InAs and increased respiratory mortality was attenuated. Upon fur-
ther examination of Smith et al. (1998), however, the highest rates of
COPD mortality were among adults aged 30–39 year olds who were
exposed to high levels of InAs in utero and during childhood.
3.6.3. Sex differences
Four articles stratiﬁed their ﬁndings by sex (Tsai et al., 1999;
Smith et al., 1998, 2006, 2011). Evidence of sex-speciﬁc effects was
heterogeneous. In Smith et al. (2011), men had higher rates of
pulmonary tuberculosis mortality than women. However, women
Table 6
Evidence table on InAs and non-malignant lung disease mortality.
Reference Location Age (yrs) Exposure level Outcome Sex Effect estimate 95% CI Comments
Study Design Size
−Ecological level water arsenic
Smith et al. (2011) Chile Exp:All Ecological Pulmonary TB Male Rate ratio 1.58 1.34, 1.85 Adj:age. Mortality:1986–2000. ICD-10 codes A15-16 reverted to
ICD-9 code 011.
Ecological Out:All Female Rate ratio 1.48 1.11, 1.97
Smith et al. (2006) Chile Exp:in utero National Bronchiectasis All SMR 46.2 21.1, 87.7 Mortality data from 1989-2000. ICD-9 codes for COPD:490, 491,
492, and 496, and Bronchiectasis:494.
Ecological Out:30–49 Reference Male SMR 36.4 4.1, 132.0
Female SMR 50.1 20.0,
103.0
Other COPD All SMR 7.6 3.0, 15.6
Male SMR 3.6 0.4, 12.9
Female SMR 13.7 4.4, 32.0
Tsai et al. (1999) Taiwan Exp:All National Bronchitis Male SMR 1.87 1.59, 2.18 Mortality data from 1971 to 1994. Also includes local reference
SMRs and SMRs for asthma. ICD-8 and ICD-9 codes for Bron-
chitis:490–491, Emphysema:492.
Ecological Out:All Reference Female SMR 1.95 1.65, 2.29
Emphysema Male SMR 0.76 0.52, 1.08
Female SMR 0.90 0.52, 1.47
Smith et al. (1998) Chile Exp:All National COPD Male SMR 1.0 0.8, 1.1 Mortality data:1989–1993. ICD-9 codes:COPD codes 490–496,
excluding 493.
Ecological Out:≥30 Reference Female SMR 0.6 0.4, 0.7
Urinary arsenic publications
Argos et al. (2014) Bangladesh Exp:Adults ≥ μ332.0 g/g Cr NMLD All Hazard ratio 1.75 1.15, 2.66 By tertiles. Adj:sex, age, BMI, edu, smoking, and study cohort.
Reports results using wAs and skin lesion status as exposure.
ICD-10 codes J00-J99 and I27.
Longitudinal n¼26,043 Out:Adults vs. < μ132.5 g/g Cr
220,157 prsn-yrs
Publications further organized by date. wAs and uAs in μg/L unless otherwise noted. Abbreviations: Exp, age at exposure; Out, age at outcome; uAs, urinary arsenic; Cr, creatinine; SMR, standardized mortality ratio; CI, conﬁdence
interval; ICD, International Classiﬁcation of Diseases; TB, tuberculosis; COPD, chronic obstructive pulmonary disease; NMLD, non-malignant lung disease; n, study size; and prsn-yrs, person-years.
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T.R. Sanchez et al. / Environmental Research 147 (2016) 537–555552had higher SMRs for chronic bronchitis, bronchiectasis and “other
COPD” compared to men in articles by Smith et al. (2006) and Tsai
et al. (1999). Interestingly, in Smith et al. (1998), the SMR for COPD
was null among men, but InAs exposed women had statistically
signiﬁcantly lower SMR for COPD.
3.6.4. Dosimetry
Effect estimates were generally higher in the publications from
Chile than in the publications in Taiwan or Bangladesh. Of note,
exposure in Chile (mean = μwAs 870 g/L) was much higher than in
Bangladesh (mean ≈ μwAs 34.5 g/L). Argos et al. (2014) presented
evidence on the exposure–response relationship. This publication
found a statistically signiﬁcant trend between increasing tertile of
uAs and increasing magnitude of effect on non-malignant lung
disease mortality.4. Discussion
This systematic review provides an extensive introduction to
the ﬁeld and should be used to guide future research on InAs and
respiratory health. Our review identiﬁes 29 publications that ex-
amine how InAs exposure maybe associated with different facets
of respiratory health, including consistent evidence on lung func-
tion impairment, acute respiratory tract infections, respiratory
symptoms, and non-malignant lung disease mortality particularly
at high levels of exposure. Our review also uncovers some com-
mon shortcomings in this body of evidence, including incomplete
exposure histories, poorly deﬁned outcomes and limited con-
founder control.
4.1. Limitations
While acknowledging the importance of our ﬁndings, there are
some limitations worth noting. As with any systematic review, our
ﬁndings may have been affected by publication bias. However, we
have searched two complimentary databases and have performed
an intensive gray literature search. The term non-malignant lung
disease is loosely used to describe the non-cancerous effects of
InAs on respiratory system. We have attempted to organize out-
comes by clinically meaningful categories but this approach could
have unintentionally complicated our interpretation of the re-
lationship between InAs and lung disease. Our adapted quality
assessment questionnaire is somewhat problematic. A publication
may appear to be of higher or lower quality because the binary
quality assessment was unable to capture nuanced details or au-
thors failed to report needed details. Thus, interpreting how well a
study did on our quality assessment should be done with caution.
Several articles have used inappropriate reference values to pre-
dict lung function estimates. In lieu of presenting the evidence on
lung function using set cut-points to deﬁne obstructive and re-
strictive lung disease, we have chosen to present lung function as a
continuous measure. While this is less clinically meaningful, we
believe the former classiﬁcation would have been misleading.
4.2. Summary of ﬁndings
Although the ﬁndings from this systematic review show strong
evidence of a general association between InAs and non-malignant
respiratory illnesses, there is somewhat more uncertainty of a
relationship between InAs and any single non-malignant re-
spiratory outcome or pathological process. Arsenic could poten-
tially contribute to different non-malignant lung diseases through
several mechanisms, including altered wound repair, increased
inﬂammation, and immune system dysregulation. Exactly how
and which of these pathways contribute to non-malignant lungdisease is still poorly understood and should be further
investigated.
This review found strong evidence of an association between
increasing InAs and decrements in FVC and FEV1. Some in vitro
evidence indicates InAs exposure may alter the expression of an
important protease in lung function, matrix metalloproteinase
(MMP-9), and alter ATP-dependent Ca2þ signaling (Sherwood
et al., 2011; Olsen et al., 2008). Both in turn could affect the sig-
naling pathways for cell migration and alter the airway epithelial
barrier by restricting proper wound repair and compromising in-
nate airway defense mechanisms.
Alternatively, there is some evidence that reduced lung func-
tion is associated with increased risk for future cardiovascular
morbidity and mortality (Sin et al., 2005; Yoon et al., 2014), an-
other health system strongly associated with InAs exposure and
increased inﬂammation (Abhyankar et al., 2012; Navas-Acien et al.,
2005). This is also supported by some recent epidemiologic evi-
dence of lung inﬂammation biomarkers and lung function (Olivas-
Calderon et al., 2015; Parvez et al., 2008). Although evidence in
this review on InAs and lung function in children was inconsistent,
a reduction in FVC in young adulthood has been associated with
diastolic dysfunction in middle age (Cuttica et al., 2015). Two
publications in this review hint at InAs and cardiopulmonary ef-
fects: Argos et al. (2014) in their linkage of exposure to pulmonary
hypertension mortality and Bhattacharyya et al. (2014) in their
examination of pulmonary arterial dilatation. Together, these
ﬁndings add to the complex yet understudied interplay between
the cardiovascular and pulmonary systems in relation to InAs
exposure.
Chronic InAs exposure may also have biphasic effects on the
immune system. In an in vivo model of inﬂuenza infection, among
mice having ﬁrst been exposed to μ100 g/L wAs, Kozul et al. (2009)
observed that InAs exposed mice ﬁrst display a compromised
immune response to respiratory infections, but at later time
points, these mice display an excessive cellular inﬂammatory re-
sponse. The current review found some evidence of positive re-
lationship between in utero InAs exposure and acute respiratory
tract infections among infants and compelling evidence on
bronchiectasis among adults. Additionally, respiratory symptoms
like chronic productive cough and reoccurring RTI may be early
signs of non-cystic-ﬁbrosis bronchiectasis (Pasteur et al., 2010).
The heterogeneity of the chronic non-malignant lung diseases
examined is indicative of a potential area for future research. The
publications on chronic non-malignant lung disease have some
limitations, including insufﬁcient confounder control and disease
prevalence rather than incidence. While we believe there is
compelling evidence on bronchiectasis, it is based on only two
publications (Mazumder et al., 2005; Smith et al., 2006). In Ban-
gladesh, Mazumder et al. (2005) found the odds of CT-diagnosed
bronchiectasis among participants with skin lesions was 10 times
that of participants without skin lesions, after adjusting for age,
sex, smoking and self-reported tuberculosis history. The size of
this effect estimate is compelling given the results are based on 21
total cases of bronchiectasis. There is also strong evidence on
bronchiectasis mortality. In Chile, Smith et al. (2006) reports the
SMR for bronchiectasis for men and women exposed to very high
InAs levels in utero and early childhood was more than 46 times
that of the rest of the country, although results were based on nine
total cases of bronchiectasis.
Research elucidating the pathophysiology of a single non-ma-
lignant lung disease as it relates to InAs exposure, like bronch-
iectasis, based on a careful clinical diagnosis of disease and a
strong history and range of InAs exposure, would help corroborate
these ﬁndings and further our understanding of the relationship
between InAs and a single non-malignant respiratory outcome or
pathological process.
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posure in utero and during early life can have detrimental health
consequences throughout the lifespan. This review ﬁnds adverse
respiratory consequences that can be detected even in the ﬁrst
months of life. There is some evidence that in utero InAs exposure
increased both the frequency and severity of RTI among infants
(Rahman et al., 2011; Farzan et al., 2015). Yet less evidence on the
potential effects of early life arsenic exposure among adolescents.
There is also strong evidence that mortality later in life is most
pronounced when exposure occurs in utero and at very high levels.
People exposed early in life seemingly die at a younger age and at
greater numbers compared to those exposed to InAs only in
adulthood or later in childhood (Smith et al., 2006, 2011). How-
ever, less is known about the mechanisms that contribute to latent
disease development (Bailey et al., 2016).
Sex differences. Publications on other health effects related to
InAs exposure indicate that men and women seem to be suscep-
tible to different types of effects (Vahter et al., 2007). In general,
effect estimates for InAs and lung function, respiratory symptoms,
infection, and non-malignant lung disease morbidity seem to be
stronger in men than in women; however, effect estimates for InAs
and non-malignant lung disease mortality seem to be stronger in
women than in men. Sex differences in arsenic metabolism may
also lend biological plausibility to the aforementioned differences.
Inorganic arsenic is biomethylated in the body and forms mono-
methylarsonic acid (MMA) and dimethylarsinic acid (DMA). Me-
thylated arsenicals are excreted more rapidly in urine than InAs;
however, the trivalent forms of the methylated metabolites,
MMAIII and DMAIII, are thought to be the most toxic species
(Thomas et al., 2007). Several studies indicate that women have
better methylation efﬁciency, as suggested by higher percentage of
DMA and less MMA, compared to men (Lindberg et al., 2008;
Gamble et al., 2005), perhaps contributing to the increased mor-
bidity in men.
Dosimetry. Although we had intended to perform a subgroup
analysis on low-level wAs exposure ( < μ )wAs 100 g/L , wAs levels
in most publications > μwas 100 g/L . Thus low-level effects are
still poorly understood. Additionally, publications used different
measures of exposure and incorporated different exposure con-
trasts, thus making it difﬁcult to study whether similar exposure
levels yielded similar effect estimates.
Of note, six of the included publications used the presence of
arsenic-induced skin lesions as the primary exposure marker.
While their presence may conﬁrm prior InAs exposure, their ab-
sence does not exclude exposure. Arsenic-induced skin lesions are
early biomarkers of effect (Haque et al., 2003). The presence of
skin lesions also represents susceptibility to a certain degree, as
not all people chronically exposed to InAs develop lesions and
those with lesions appear to be susceptible to other adverse health
outcomes, including lung and bladder cancer (Cuzick et al., 1984,
1992). Indeed, three articles in this review also ﬁnd a greater
magnitude of effect (on lung function, respiratory symptoms and
non-malignant lung disease mortality) among people with skin
lesions compared to InAs exposed people without skin lesions
(von Ehrenstein et al., 2005; Ghosh et al., 2007; Argos et al., 2014).
4.3. Conclusions
In this systematic review we have summarized the epidemio-
logic literature on different ways in which InAs is associated with
respiratory health to better inform stakeholders on the existing
evidence in this ﬁeld and to identify future avenues of research. In
short, associations between InAs and respiratory health have been
noted throughout the lifespan: in infancy, there is growing evi-
dence that in utero InAs exposure is associated with increased
frequency and severity of respiratory tract infections; in childhood,evidence of respiratory symptoms also begin to appear; and in
adulthood, there is consistent evidence that InAs exposure is as-
sociated with deﬁcits in lung function (particularly FVC) and in-
creased reports of coughing and breathing problems. Limitations
including potential publication bias; non-comparability of out-
come measures across publications; incomplete exposure his-
tories; potential effect modiﬁcation by smoking; insufﬁcient ad-
justment for indoor/outdoor air pollution and other important
confounders attenuated the cumulative strength of the evidence
on InAs and non-malignant lung disease as it relates to US popu-
lations. Greater attention should be paid both to examining whe-
ther sex differences exist and further elucidating the dose–re-
sponse relationship between InAs and respiratory health, parti-
cularly at wAs levels < μ100 g/L. Early life InAs exposure appears to
have lasting effects on the respiratory system. This extensive re-
view should be used to guide future research in order to deﬁne
relevant mechanisms involved and implement effective public
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